Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Robert G. Maki, MD, PhD, FACP

Cancer.Net Associate Editor: Sarcoma
Mount Sinai School of Medicine, New York, NY

Dr. Robert Maki is Professor of Medicine, Pediatrics, and Orthopedics, and the Steven Ravitch Chair in Pediatric Hematology-Oncology at Mount Sinai School of Medicine in New York, NY. He has published over 100 articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and children with sarcomas (connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue) and has an interest in translational research and the biology that leads to different types of sarcomas.

Dr. Maki earned his medical and doctorate degree at Cornell University Medical College in New York City. He completed his residency at Brigham and Women's Hospital in Boston before completing his medical oncology fellowship at Dana-Farber, also in Boston.

After developing a sarcoma medical oncology program at Memorial Sloan-Kettering Cancer Center, Dr. Maki moved uptown to the Mount Sinai Medical Center in New York to expand the efforts in adult sarcoma therapy and translational research. Dr. Maki has broad interests in the biology of sarcomas of soft tissue and bone, as well as clinical trials and new drug development for this diverse group of diseases, and he has participated extensively in numerous national and international studies in sarcoma.

Dr. Maki also leads the Pediatric Hematology-Oncology program at Mount Sinai, where he continues his personal interest in the care of adolescents with sarcomas, while also expanding the role of the Pediatric Hematology-Oncology program in the treatment and research of pediatric cancers.

Disclosure: In the past two years, Dr. Maki has served as a consultant/advisor to Bayer, Novartis, Lilly, Pharma Mar, Merck, GlaxoSmithKline, Morphotek, Eisai, n-of-one, Foundation Medicine, and 23 & me; he has also received honoraria from ZIOPHARM Oncology, as well as research funding from Pfizer, Roche, Lilly, Eisai, and Hyundai Hope on Wheels.

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: